You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Image of a fictitious patient and healthcare professional

Resources

We have created a range of expert lead video content and downloadable resources to support you and your advanced ovarian cancer patients who have been prescribed ZEJULA.

Journal Article Resources

EJC 2023: Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancerClick Here

Authors: Gonzalez-Martin et al

ZEJULA is indicated1

  • as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
  • as monotherapy for the maintenance treatment of adult patients with platinumsensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Footnotes

HCP, healthcare professional; MoA, mechanism of action; QoL, quality of life.

References

  1. ZEJULA Summary of Product Characteristics.
  2. González-Martín A;European Journal of Cancer;2023;1-13

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Zejula is a registered trademark of the GlaxoSmithKline group of companies.

November 2023 PM-IE-NRP-WCNT-230013